EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Laggard

By TheStreet Wire 07/31/12 - 05:01 PM EDT

Find out if (TEVA) is in Cramer's Portfolio.

Teva Pharmaceutical Industries (TEVA) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.4%. By the end of trading, Teva Pharmaceutical Industries fell 33 cents (-0.8%) to $40.89 on light volume. Throughout the day, 1.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.8 million shares. The stock ranged in price between $40.45-$41.29 after having opened the day at $40.47 as compared to the previous trading day's close of $41.22. Other company's within the Drugs industry that declined today were: Dendreon (DNDN), down 23%, Savient Pharmaceuticals (SVNT), down 12.2%, K-V Pharmaceutical Company (KV.A), down 10.7%, and Arena Pharmaceuticals (ARNA), down 10.4%.

ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $36 billion and is part of the health care sector. The company has a P/E ratio of 13.4, above the average drugs industry P/E ratio of 12.8 and below the S&P 500 P/E ratio of 17.7. Shares are up 2.1% year to date as of the close of trading on Monday. Currently there are 20 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself.

You can view the full Teva Ratings Report.

On the positive front, Amyris (AMRS), up 9.3%, China Pharma (CPHI), up 9.1%, Impax Laboratories (IPXL), up 8.3%, and IGI (IG), up 6.9%, were all gainers within the drugs industry with Novartis (NVS) being today's featured drugs industry leader.

Use our drugs section to find industry-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

Find other investment ideas from our top rated ETFs lists.

For more information on Teva Pharmaceutical Industries Ltd click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.